Abstract:Importance: Accurate diagnosis of tuberculosis (TB) infection can be achieved with interferon gamma ; release assays. Their performance can be improved by utilizing fully automated, single–patient formats. Objective: Establish clinical thresholds for a new interferon gamma; release assay, the VIDAS® TB–IGRA, and compare diagnostic performance in detecting tuberculosis infection and disease with the established QuantiFERON–TB Gold Plus (QFT–Plus). Design: Preliminary diagnostic performance study (October 2nd, 2019 to February 20th, 2020). Setting: Multicenter. Participants: Participants were divided into TB disease, high–risk, and low–risk populations. The confirmed TB disease population included 107 patients. The high–risk population included 162 individuals with flagged risk factors on a questionnaire but without objective clinical confirmation of TB. The Low–risk population included 117 healthy blood donors from the French National Blood Bank. Exposures: Tuberculosis. Main Outcomes and Measures: Positive and negative percent agreement (PPA, NPA) were determined between the VIDAS® TB–IGRA and QFT–Plus. In the TB disease and low–risk populations, sensitivity was also measured against bacterial culture and PCR. Results: The VIDAS® TB–IGRA produced fewer indeterminate results than the QFT–Plus (1/107 vs. 23/107) in the TB disease population. One analysis included indeterminate results as false negatives (94 positives and 10 false negatives vs. 56 positives and 48 false negatives), and the VIDAS® TB–IGRA exhibited higher sensitivity than the QFT–Plus (90.4% vs. 53.8%) (p<0.0001). Another analysis excluded indeterminate results (76 positives and 4 false negatives vs. 55 positives and 25 false negatives), and the VIDAS® TB–IGRA again exhibited higher sensitivity than the QFT–Plus (95.0% vs. 68.8%) (p<0.0001). A 98.2% PPA was calculated between the two tests with this dataset. In the high–risk population, the VIDAS® TB–IGRA exhibited a strong PPA (94.4%) with the QFT–Plus. However, a lower than expected NPA was observed (85.2%). In the low–risk population, the VIDAS® TB–IGRA demonstrated high specificity (94.9%) and a strong NPA (98.2%) with the QFT–Plus. Conclusions and Relevance: The fully automated VIDAS® TB–IGRA is a promising diagnostic test for both TB infection and disease. It exhibits higher sensitivity while maintaining specificity and produces fewer indeterminate interpretations. Its easy–to–use, single–patient format may lead to increased TB testing to help with the worldwide eradication of the disease.

Pulmonary tuberculosis diagnostic test using fluorescence immunoassay-based interferon gamma release assay with IchromaTM IGRA-TB

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

Clinical Application of Interferon-Gamma Release Assays for Diagnosis of Pulmonary Tuberculosis and Extrapulmonary Tuberculosis

Tuberculin skin test and Interferon-gamma release assay agreement, and associated factors with latent tuberculosis infection, in medical and nursing students in Bandung, Indonesia

Performance of Xpert MTB/RIF and sputum microscopy compared to sputum culture for diagnosis of tuberculosis in seven hospitals in Indonesia

Interferon-Gamma Release Assay Performance In Pulmonary And Extrapulmonary Tuberculosis

Evaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis

[Interferon Gamma Release Assay Request Indications: From Laboratory to Clinical Perspective]

Utility of Cerebrospinal Fluid Unstimulated Interferon-Gamma (IRISA-TB) as a Same-Day Test for Tuberculous Meningitis in a Tuberculosis-Endemic, Resource-Poor Setting

Interferon-Gamma Release Assay Performance of Pleural Fluid and Peripheral Blood in Pleural Tuberculosis

Evaluation of a Domestic Interferon-Gamma Release Assay for Detecting Mycobacterium Tuberculosis Infection in China.

Diagnostic Performance of Unstimulated IFN-γ (IRISA-TB) for Pleural Tuberculosis: A Prospective Study in South Africa and India

A Retrospective Study on Xpert MTB/RIF for Detection of Tuberculosis in a Teaching Hospital in China.

Effect of tuberculosis-specific antigen stimulation on the diagnostic accuracy of interferon-γ inducible protein-10 in distinguishing active and latent tuberculosis infection: a meta-analysis

Diagnostic accuracy of the IFN-γ release assay using RD1 immunodominant T-cell antigens for diagnosis of extrapulmonary tuberculosis

Development And Evaluation Of A New Interferon-Gamma Release Assay For The Diagnosis Of Tuberculosis Infection In Hiv-Infected Individuals In China

Preliminary diagnostic performance of the VIDAS® TB-IGRA for the detection of Mycobacterium tuberculosis infection and disease

Diagnostic applications of TB-IGRA and TST in patients with culture-positive tuberculosis

Evaluation of a New IFN-γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting.

Performance of Interferon-Gamma Release Assays in the Diagnosis of Nontuberculous Mycobacterial Diseases—A Retrospective Survey from 2011 to 2019

Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis